Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

Elmind Capital LP purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 984,931 shares of the company’s stock, valued at approximately $18,093,182,000. Viridian Therapeutics comprises about 4.5% of Elmind Capital LP’s portfolio, making the stock its 8th largest position. Elmind Capital LP owned 0.87% of Viridian Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of VRDN. KBC Group NV purchased a new stake in shares of Viridian Therapeutics during the first quarter worth about $34,000. ANTIPODES PARTNERS Ltd purchased a new position in Viridian Therapeutics during the 4th quarter valued at about $36,000. State of Wyoming purchased a new position in Viridian Therapeutics during the 2nd quarter valued at about $43,000. Larson Financial Group LLC bought a new position in Viridian Therapeutics during the 3rd quarter valued at approximately $52,000. Finally, US Bancorp DE raised its position in Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the last quarter.

Viridian Therapeutics Stock Up 0.7%

VRDN stock opened at $24.18 on Wednesday. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The business’s 50 day moving average price is $20.14 and its two-hundred day moving average price is $20.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -7.18 and a beta of 0.91.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. As a group, analysts forecast that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VRDN has been the topic of a number of recent analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $39.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Truist Financial upped their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Weiss Ratings lowered Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Finally, Royal Bank Of Canada boosted their price objective on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.54.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.40% of the company’s stock.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.